L01XC27 • olaratumab • Antineoplastic and immunomodulating agents | Other antineoplastic agents | Monoclonal antibodies
Olaratumab is a monoclonal antibody used for the treatment of advanced soft tissue sarcoma, in combination with doxorubicin. It works by blocking the platelet-derived growth factor receptor alpha (PDGFR-α), thereby inhibiting the growth and spread of cancer cells.
The medication is administered intravenously, as directed by your doctor, usually in treatment cycles. It is important to monitor side effects and undergo regular tests to assess the effectiveness of the treatment.
Side effects may include nausea, fatigue, neutropenia, injection site reactions, or, in rare cases, severe allergic reactions.
Patients should inform their doctor about any other medications being used or pre-existing conditions to ensure the safe use of olaratumab.
Substance: olaratumab
Date of last drug list: 01-07-2020
Commercial code: W63494002
Concentration: 10mg / ml
Pharmaceutical form: perfusive solution concentrate
Quantity: 2
Product type: original
Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).